Stocks to Watch Wednesday - BMTL, ANGO, JNPR

SmallCapReview.com is a leading small cap stock information site since 1999, to register for the free SmallCapReview newsletter visit http://www.smallcapreview.com.

Biomedical Technology Solutions Holdings (OTCBB: BMTL) $0.35. Announced Tuesday after market close  the BMTL in-store Demolizer II Sharps Disposal Program and the placement of its first Demolizer II in a Kroger pharmacy. This program is designed to establish a valuable, full service sharps life cycle solution to pharmacy syringe customers. With over 2000 retail pharmacy outlets in the U.S., the placement of the first system in a Kroger pharmacy is an important benchmark for BMTL.

BMTL believes this program will help to build national awareness of the growing public health and environmental problems associated with the improper or unsafe transportation and disposal of sharps waste generated at home. By establishing a safe, environmentally friendly and convenient in-store disposal method BMTL hopes to encourage the estimated 9 million people in the U.S. that administer 3 billion injections at home annually to take advantage of the in-store Demolizer II sharps disposal program.

The first of its kind, this in-store sharps disposal program provides a safe and environmentally friendly biomedical waste disposal alternative designed to enable diabetics and others using syringes at home to safely destroy their sharps waste by bringing it back to their pharmacy when replenishing treatment supplies.

Don Cox, President and CEO of BMTL, explains, "The ultimate goal of the in-store Demolizer II sharps disposal program is to establish the Demolizer II as the preferred sharps disposal system in the pharmacy market. The faster we expand our brand presence, the sooner we can start reaping financial rewards from our patented Demolizer� technology in the pharmacy program, while at the same time reducing the negative public and environmental impact of improper disposal."

AngioDynamics (Nasdaq: ANGO) $13.85. Announced After Market close Tuesday financial results for the fiscal first quarter ended August 31, 2009. 

Net sales in the first quarter were $50.1 million, a 13% increase over the $44.3 million reported in the first quarter a year ago. Gross margin was 60.2% compared with 61.9% a year ago, with the decline primarily attributable to product mix, material cost increases, a competitive pricing environment and utilization factors. Operating income was $3.6 million in the quarter compared with $3.8 million a year ago. Net income in the first quarter was $2.1 million or $0.09 per share compared with $2.2 million, or $0.09 per share a year ago. The decline in net income is primarily attributable to increased operating expenses associated with sales and marketing programs and the Company’s continuing investment in irreversible electroporation (IRE) technology. AngioDynamics reported cash and investments of $68.8 million and long-term debt of $6.7 million at August 31, 2009.

What They Do: AngioDynamics is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease.

Juniper Networks (Nasdaq: JNPR)  $26.95. Announced Tuesday after market close it has filed an application to list its common stock on the New York Stock Exchange (“NYSE”). Subject to the approval of the NYSE, Juniper expects to begin trading on the NYSE on October 29, 2009, retaining its current symbol “JNPR”. The Company will continue to trade on the Nasdaq Global Select Market until the transfer is completed.

What They Do: Juniper Networks, Inc. is the leader in high-performance networking. Juniper offers a high-performance network infrastructure that creates a responsive and trusted environment for accelerating the deployment of services and applications over a single network.